Sylvester Opens New Dysplasia Clinic
Dr. Brian M. Slomovitz (front center) and the gynecology team played a crucial role in establishing the dysplasia clinic.
Doctors strive to stop abnormal cell growth in high-risk patients before cancer develops
After months of planning and preparation, Sylvester Comprehensive Cancer Center officially launched its new dysplasia clinic on September 18. With a world-class, multidisciplinary team of physicians and researchers, the clinic offers screening and treatment for women and men who are at high risk of developing cervical, vulvar or anal cancer.
Dysplasia is a medical condition in which cells of an abnormal type proliferate, leading to the enlargement of organs or tissue. A variety of cancers, including cervical, vulvar, and anal lesions, can develop from dysplasia as abnormal cells continue to grow and mutate. Given the role certain viruses play in the development of these cancers, the clinic will focus heavily on patients with HPV and HIV.
“This clinic is the only one of its kind in South Florida,” said Brian M. Slomovitz, M.D., Director of the Gynecologic Oncology Division at Sylvester. “Prevention and early detection have the most effective impact on cure rates for these types of cancer. However, most patients are not aware of the signs and symptoms, which is why regular screenings are so important.”
Patricia P. Jeudin, M.D., a gynecologist who recently joined Sylvester from Boston Medical Center and Isabella Rosa-Cunha, M.D., an infectious disease specialist who focuses on HPV-related anal dysplasia and cancer will oversee the clinical aspects of the operation.
Offering a suite of cutting-edge diagnostics and technologies such as high-resolution anoscopy (HRA) and colposcopy, physicians will accelerate the identification of pre-cancerous lesions and more precisely diagnose each patient’s illness.
Erin L. Kobetz, Ph.D., M.P.H., Director of Disparities and Community Outreach at Sylvester, and JoNell E. Potter, ARNP, Ph.D., Director of Research and Special Projects at Sylvester, will lead the prevention, early detection and risk-stratification research.
“The clinic provides a unique opportunity to meet a critical patient need in our geographic area,” said Kobetz. “In addition, we’re conducting high-impact translational science that is interdisciplinary in orientation. We set up the clinic to provide a repository for basic scientists and other translational researchers who are interested in understanding the development of these malignancies that affect our patient population.”
By obtaining samples from dysplasia patients and using short and long-term patient data, scientists may be able to identify disease patterns and study the cells’ progression from dysplasia to cancer. These insights could then be used to eventually develop drugs that can prevent the progression into cancer cells.
For additional information about the dysplasia clinic, please call 305-243-2233.